Personalis, Inc. Common Stock
PSNL
$16.03
-2.26%
Personalis, Inc. is a healthcare diagnostics and research company that provides genomic sequencing and analytics services to support the development of personalized cancer vaccines and next-generation cancer immunotherapies. Its core offerings, including ImmunoID NeXT and NeXT Personal, are designed to enable precise tumor profiling and treatment response monitoring for biopharmaceutical partners and clinical customers. As a niche player in the precision oncology space, Personalis differentiates itself through its comprehensive, whole-genome-based approach, which offers deeper insights than traditional targeted panels. The current investor narrative centers on the company's strategic pivot toward higher-margin clinical diagnostics and its recent revenue growth acceleration, despite ongoing profitability challenges and a highly competitive landscape.…
PSNL
Personalis, Inc. Common Stock
$16.03
Related headlines
Investment Opinion: Should I buy PSNL Today?
Rating: Hold. The stock is a speculative buy at best, given the extreme valuation and deteriorating fundamentals. The consensus is 'Buy' with an average target of $13.875, which is 24.5% below the current price, indicating that the stock has overshot analyst expectations. The thesis is that the company's pivot to clinical diagnostics could drive future growth, but the current price already reflects optimistic assumptions.
Sign up to view all
PSNL 12-Month Price Forecast
The AI assessment is bearish due to the extreme disconnect between the stock price and fundamental performance. The company is losing money at an accelerating rate, and the valuation implies expectations of a dramatic turnaround that is not supported by current data. The stock's 294% rally appears speculative, and the risk of a correction is high. To upgrade the stance, we would need to see evidence of revenue stabilization, margin improvement, and analyst target revisions upward. Conversely, a downgrade would be triggered by further deterioration in revenue or a dilutive capital raise.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Personalis, Inc. Common Stock's 12-month outlook, with a consensus price target around $15.44 and implied upside of -3.7% versus the current price.
Average Target
$15.44
0 analysts
Implied Upside
-3.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$13 - $16
Analyst target range
Analyst coverage is limited, with only 4 analysts providing ratings, but the consensus is a 'Buy' with a mean recommendation score of 1.8 (where 1 is Strong Buy and 5 is Sell). The average target price is $13.875, which implies a downside of -24.5% from the current price of $18.38, indicating that the stock has surged beyond analyst expectations. The target range spans from $10.00 (low) to $16.25 (high), with the high target still below the current price, suggesting that even the most bullish analyst does not see further upside at current levels. This disconnect between the stock price and analyst targets highlights the speculative nature of the recent rally, which may be driven by factors not fully captured in analyst models, such as potential partnership announcements or clinical trial readouts. The wide spread between the low and high targets (62.5% difference) underscores the high uncertainty surrounding the company's future, and the recent ratings actions have been predominantly neutral (Morgan Stanley Equal Weight) with some Buy reiterations (BTIG, Needham), indicating a cautious but not bearish stance.
Drowning in data?
Find the real signal!
Bulls vs Bears: PSNL Investment Factors
Personalis presents a stark contrast between a surging stock price and deteriorating fundamentals. The bull case rests on the company's strategic pivot to clinical diagnostics, strong liquidity, and the potential for revenue acceleration, which has driven a 294% rally. However, the bear case is compelling: revenue is declining, losses are widening, and the stock trades at a massive premium to both analyst targets and industry valuation norms. The most critical tension is whether the recent stock surge is justified by upcoming catalysts (e.g., partnership wins, clinical trial readouts) or is a speculative bubble. Currently, the bearish evidence is stronger on a risk/reward basis, as the stock has outpaced fundamentals and analyst expectations, leaving limited upside and substantial downside risk.
Bullish
- Explosive stock momentum: PSNL has surged 294.4% over the past year, from a 52-week low of $4.652 to $18.38, and is trading just 2.7% below its 52-week high of $18.89. This reflects strong investor conviction in the company's strategic pivot and potential for future growth.
- Strong balance sheet liquidity: The company has a current ratio of 6.76, indicating ample short-term liquidity to fund operations and R&D. With a debt-to-equity ratio of only 0.15, financial leverage is minimal, reducing bankruptcy risk despite ongoing losses.
- High forward growth expectations: Analysts estimate revenue of $227.4 million for the next fiscal year, implying a forward PS ratio of approximately 3.1x, which is reasonable for a high-growth diagnostics company. This suggests the market expects significant revenue acceleration from the current run rate.
- Positive analyst sentiment: The consensus rating is 'Buy' with a mean recommendation score of 1.8 (1=Strong Buy, 5=Sell). Despite the stock trading above the average target, analysts remain constructive on the company's long-term prospects, with no Sell ratings.
Bearish
- Revenue declining sharply: Q1 2026 revenue fell 24.9% year-over-year to $15.47 million, following declines of 15.4% in Q4 2025 and 16.0% in Q3 2025. This persistent contraction contradicts the growth narrative and suggests fundamental challenges.
- Stock trades above all analyst targets: The current price of $18.38 is 32.4% above the average analyst target of $13.875 and 13.1% above the highest target of $16.25. This disconnect implies the market is pricing in outcomes that analysts have not yet incorporated, raising the risk of a correction.
- Extremely high valuation premium: The trailing PS ratio of 10.2x and EV/Sales of 23.4x are far above the diagnostics industry average of 3-5x. This premium leaves little room for error; any disappointment could trigger a severe de-rating.
- Persistent and widening losses: Net margin is -116.7%, and operating margin is -126.4%. Q1 2026 net loss was $30.0 million on revenue of just $15.5 million, with EBITDA of -$27.6 million. The company is burning cash at an unsustainable rate, with negative free cash flow of -$84.6 million TTM.
PSNL Technical Analysis
Personalis has exhibited a powerful sustained uptrend over the past year, with the stock price surging 294.4% from its 52-week low of $4.652 to the current price of $18.38, which sits just 2.7% below the 52-week high of $18.89. The stock is trading at 97.3% of its 52-week range, indicating strong bullish momentum and investor optimism. This positioning near the highs suggests the market is rewarding the company's recent operational progress, though it also raises the risk of overextension and potential profit-taking.
Beta
2.32
2.32x market volatility
Max Drawdown
-55.2%
Largest decline past year
52-Week Range
$5-$19
Price range past year
Annual Return
+122.6%
Cumulative gain past year
| Period | PSNL Return | S&P 500 |
|---|---|---|
| 1m | -6.8% | +1.2% |
| 3m | +13.6% | +4.5% |
| 6m | +163.2% | +14.6% |
| 1y | +122.6% | +16.0% |
| ytd | +104.2% | +14.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PSNL Fundamental Analysis
Revenue has shown a mixed trajectory, with the most recent quarter (Q1 2026) reporting $15.47 million, a 24.9% decline year-over-year, following a 15.4% decline in Q4 2025 and a 16.0% decline in Q3 2025. However, the sequential trend improved from $14.50 million in Q3 2025 to $17.35 million in Q4 2025, before dipping again in Q1 2026. The company's growth has been volatile, reflecting the lumpy nature of pharma collaborations and the ongoing transition toward clinical diagnostics. The revenue decline in Q1 2026 is concerning, but the recent stock surge suggests investors are looking past near-term weakness toward future catalysts.
Quarterly Revenue
$15472000.0B
2026-03
Revenue YoY Growth
-24.9%
YoY Comparison
Gross Margin
1.8%
Latest Quarter
Free Cash Flow
$-84648000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PSNL Overvalued?
Given that Personalis has negative net income and negative EBITDA, the most appropriate valuation metric is the price-to-sales (PS) ratio, which stands at 10.2x trailing and 23.4x EV/Sales. The trailing PS of 10.2x is elevated compared to the broader diagnostics industry, which typically trades at 3-5x sales, implying a significant premium. This premium reflects the market's expectation of rapid revenue growth and margin expansion as the company scales its clinical diagnostics business. However, the forward PS (based on estimated revenue of $227.4 million) would be approximately 3.1x, suggesting that the market is pricing in substantial growth, but the current valuation already embeds optimistic assumptions.
PE
-8.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-8.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are severe. The company is deeply unprofitable, with a net margin of -116.7% and operating margin of -126.4% in the most recent quarter. Revenue declined 24.9% YoY in Q1 2026, and the gross margin collapsed to just 1.8% (from 35.0% in Q1 2025), indicating a severe cost structure issue. The company burned $84.6 million in free cash flow over the trailing twelve months, and with a market cap of $710 million, it has roughly 8 years of cash runway at current burn rates, but this assumes no further deterioration. The high current ratio of 6.76 provides a buffer, but the negative EBITDA and reliance on external funding make the financial position precarious if revenue does not recover.
